Yeh discusses how the StemoniX microOrgan platforms and specialized AI AnalytiX™ software are driving drug discovery and development.
MAPLE GROVE, MN, JUNE 9, 2020 – StemoniX ® , Inc., a biotech company revolutionizing how new medicines are discovered, announced today that its CEO and Co-founder, Ping Yeh, has joined a panel of experts from the FDA, the NIH, Pharma, and AI at this year’s BIO2020 Digital conference.
The panel, titled Organs-on-a-Chip and AI: Realizing Potential Efficiencies in Drug Discovery and Development explores how AI can be used in conjunction with iPSC technology to reduce animal testing, ameliorate early drug discovery, and thwart late-stage drug failures. StemoniX industrializes in vitro human organoid platforms that can be applied across many
neurological, cardiac, and pancreatic diseases to identify treatments for debilitating disorders. These microOrgan platforms are being recognized across the entire drug discovery process: from phenotypic and/or targeted screening to identify new therapeutic modalities, through target identification and compound validation spurring new development, to safety and toxicity testing that brings about the next generation of medicines.
Joining Mr. Yeh on the panel are four leaders in the field of drug discovery and toxicology: Brian Berridge PhD, Sandra Engle PhD, Suzanne Fitzpatrick PhD, and Abraham Heifets PhD.
“As this pandemic has shown us, we need to be able to quickly identify novel and repurpose drugs,” said Mr. Yeh. “Using scalable organoid systems, such as the StemoniX microOrgan platforms, for high-throughput studies of AI-identified compounds offers the capability to deliver quality, functional
medications at significant time and cost savings. It was an honor to discuss the intersection of drug discovery and AI with these representative leaders within the field.”
Details of the Organs-on-a-Chip and AI panel discussion are as follows:
Event: BIO2020 Digital International Convention
Panel: Organs-on-a-Chip and AI: Realizing Potential Efficiencies in Drug Discovery and Development
Date/Time: On Demand Monday, June 8-Friday, June 12, 2020
Location: https://www.bio.org/events/bio-digital/sessions/616921
Panelists:
- Brian Berridge DVM, PhD, DACVP Moderator Associate Director of the National Toxicology Program (NTP) and the Scientific Director of the NTP Division at the NIEHS in Research Triangle Park (RTP), NC
- Sandra Engle, PhD Director, Translational Cell Sciences, Stem Cells and Genomic Engineering at Biogen
- Suzanne Fitzpatrick, PhD Senior Advisor for Toxicology Food Safety and Applied Nutrition/FDA
- Abraham Heifets, PhD, CEO and Co-Founder, Atomwise, Inc.
- Ping Yeh, MBA, Co-founder and CEO StemoniX, Inc.
About StemoniX
StemoniX is empowering the discovery of new medicines to treat challenging diseases with industrialized organoid platforms that are accurate, consistent, and predictive. In leading the convergence of drug discovery, biology, and AI/machine learning, the company partners with
pharma, biotech, government, and academic organizations to provide ready-to-use spheroids, a variety of screening and experimental services, as well as customized organoid models and assays tailored to individual discovery and toxicity needs. Visit www.stemonix.com to learn how StemoniX is helping global institutions humanize drug discovery and development to bring the most promising medicines to patients.
Contact:
Blake Anson, PhD
Vice President Business Development
StemoniX, Inc.
[email protected]
608-345-1267
